OBESE FEMALE SHHF/Mcc-fa^cp RATS RESIST ANTIHYPERTENSIVE EFFECTS OF RENIN-ANGIOTENSIN SYSTEM INHIBITION

Abstract

Gender and obesity may influence response to pharmacological modulation of the renin-angiotensin system. We used SHHF/Mcc-fa^cp rats to study effect of obesity and gender on the ability of an AT₁ receptor antagonist to decrease blood pressure. After 2 weeks treatment with irbesartan (50 mg/kg), only lean and obese males showed significant decreases in blood pressure, while obese females were completely resistant. Lean females showed a trend toward lowering of pressure (p = 0.06). However, irbesartan similarly shifted angiotensin II dose response curves to the right in all groups. Twelve weeks of irbesartan also failed to decrease blood pressure, but did significantly reduce heart weight in obese females. In untreated rats, obese females had lower plasma renin activity and serum angiotensin converting enzyme activity compared to lean males, while lean and obese females had increased urinary endothelin excretion. Despite an otherwise similar genetic background contributing to hypertension and heart failure, obese females have different patterns of humoral activation compared to lean males, which may contribute to their resistance to the depressor effects of irbesartan.

• Hypertension
• SHHF/Mcc-fa^cp rats
• Renin-angiotensin system
• Obesity
• Female
• Angiotensin receptor blockers
• Endothelin